Calendario de promoción Neoleukin Therapeutics, Inc.
Horario avanzado
gráfico sencillo
Acerca de la empresa Neoleukin Therapeutics, Inc.
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. más detalles| IPO date | 2014-03-07 |
|---|---|
| ISIN | US64049K1043 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.neoleukin.com |
| Цена ао | 15.1 |
| Cambio de precio por día: | 0% (15.1) |
|---|---|
| Cambio de precio por semana.: | 0% (15.1) |
| Cambio de precio por mes: | 0% (15.1) |
| Cambio de precio en 3 meses.: | 0% (15.1) |
| Cambio de precio en seis meses: | 0% (15.1) |
| Cambio de precio por año: | 0% (15.1) |
| Cambio de precio en 3 años.: | +489.84% (2.56) |
| Cambio de precio en 5 años.: | +25.42% (12.04) |
| Cambio de precio en 10 años.: | 0% (15.1) |
| Cambio de precio desde principios de año.: | 0% (15.1) |
|
|
Subestimación
|
Eficiencia
|
|||||||||||||||||||||||||||||||||||||
Dividendos
|
Deber
|
Impulso de crecimiento
|
|||||||||||||||||||||||||||||||||||||
| Instituciones | Volumen | Compartir, % |
|---|---|---|
| Baker Brothers Advisors, LLC | 1221414 | 13 |
| Redmile Group, LLC | 582443 | 6.2 |
| Adage Capital Partners GP L.L.C. | 310000 | 3.3 |
| Nantahala Capital Management, LLC | 299999 | 3.19 |
| Bank of America Corporation | 231779 | 2.47 |
| Vanguard Group Inc | 201539 | 2.14 |
| Renaissance Technologies, LLC | 163447 | 1.74 |
| Morgan Stanley | 107671 | 1.15 |
| Bml Capital Management, LLC | 98664 | 1.05 |
| Blackrock Inc. | 96613 | 1.03 |
| Supervisor | Título profesional | Pago | año de nacimiento |
|---|---|---|---|
| Ms. Donna M. Cochener-Metcalfe J.D. | Gen. Counsel & Sr. VP of Legal | 403.75k | 1975 (50 años) |
| Mr. Sean Michael Smith | Principal Accounting Officer, VP of Fin. & Controller | N/A | 1986 (39 años) |
| Dr. Jonathan G. Drachman M.D. | CEO, Pres, Principal Financial Officer & Director | 1962 (63 año) | |
| Dr. Priti Patel M.D., M.S. | Chief Medical Officer | 1976 (49 años) | |
| Dr. David Baker | Co-founder & Member of Scientific Advisory Board | ||
| Dr. Carl Walkey Ph.D. | Sr. VP of Corp. Devel. | 1985 (40 años) | |
| Mr. Kamran Alam | Sr. Strategic Advisor | 1974 (51 año) | |
| Dr. Bill Arthur | VP & Head of Research | ||
| Mr. Umut Ulge | VP of Clinical Devel. |
DIRECCIÓN: United States, Seattle. WA, 188 East Blaine Street - abrir en mapas de google, abrir mapas de Yandex
Sitio web: https://www.neoleukin.com
Sitio web: https://www.neoleukin.com
